uniQure (NASDAQ:QURE) Given a $35.00 Price Target by Chardan Capital Analysts

uniQure (NASDAQ:QURE) has been given a $35.00 price objective by equities researchers at Chardan Capital in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective would suggest a potential upside of 151.44% from the company’s current price.

QURE has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald raised shares of uniQure to a “strong-buy” rating in a research note on Monday, May 19th. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Finally, Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.55.

uniQure Stock Performance

QURE traded down $0.54 on Tuesday, reaching $13.92. The company had a trading volume of 1,223,243 shares, compared to its average volume of 1,427,347. uniQure has a fifty-two week low of $4.45 and a fifty-two week high of $19.18. The stock has a market cap of $762.48 million, a P/E ratio of -3.55 and a beta of 0.08. The company’s fifty day moving average is $14.89 and its 200 day moving average is $13.68. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 9.98.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In other uniQure news, Director Rachelle Suzanne Jacques sold 2,112 shares of the business’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director directly owned 28,346 shares in the company, valued at $409,599.70. The trade was a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeannette Potts sold 4,670 shares of the business’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the transaction, the insider owned 115,073 shares in the company, valued at approximately $1,742,205.22. The trade was a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,144 shares of company stock valued at $322,426 in the last quarter. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new stake in uniQure during the 2nd quarter worth approximately $117,000. ADAR1 Capital Management LLC purchased a new position in uniQure in the 4th quarter worth approximately $177,000. Mraz Amerine & Associates Inc. purchased a new position in uniQure in the 1st quarter worth approximately $106,000. Wells Fargo & Company MN grew its stake in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after buying an additional 1,503 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new position in uniQure in the 1st quarter worth approximately $152,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.